title: Long-term complications in Hodgkin's lymphoma survivors.
abstract: Background. Although patients with Hodgkin's lymphoma (HL) achieve prolonged survival, long-term complications are a major cause of morbidity and mortality among long-term survivors of HL. Methods. We retrospectively evaluated long-term complications in 336 HL survivors treated between January 1990 and January 2006 at the Department of Medical Oncology of the Hacettepe University Institute of Oncology who were >16 years old at presentation. All patients were regularly followed up every 3 months for the first 2 years after complete response, biannually for 3 years, and annually after 5 years. Results. Median follow-up was 8.5 years. The mean age (±SD) of the patients at the time of diagnosis was 35.7 ± 13.1 years. The male to female ratio was 61%/39%. During follow-up, 29 second malignancies (8.6%) were diagnosed in 28 patients with HL; 22 were solid tumors and 7 were hematological malignancies. Forty-seven (14.0%) of all patients with HL were found to have thyroid abnormalities. During follow-up, 54 (16.1%) patients developed cardiovascular complications. Overall, 29 (8.6%) patients developed late pulmonary toxicities. The cumulative number of chronic viral infections was 13 (3.9%). Conclusions. Long-term survivors of HL need to be properly followed up not only for disease control but also for evaluation of possible late morbidities to minimize the consequences.
authors.affiliation: Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey. skilickap@yahoo.com
authors.forename: Saadettin
authors.initials: S
authors.lastname: Kilickap
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Barista
authors.forename: Sukran
authors.initials: S
authors.lastname: Ulger
authors.forename: Ismail
authors.initials: I
authors.lastname: Celik
authors.forename: Ugur
authors.initials: U
authors.lastname: Selek
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Güllü
authors.forename: Ferah
authors.initials: F
authors.lastname: Yildiz
authors.forename: Ayse
authors.initials: A
authors.lastname: Kars
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Ozisik
authors.forename: Gülten
authors.initials: G
authors.lastname: Tekuzman
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology; D002319:Cardiovascular System / Q000187:drug effects / Q000528:radiation effects; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007037:Hypothyroidism / Q000453:epidemiology* / Q000209:etiology; D008171:Lung Diseases / Q000453:epidemiology* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000209:etiology; D015995:Prevalence; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012137:Respiratory System / Q000187:drug effects / Q000528:radiation effects; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D017741:Survivors / Q000706:statistics & numerical data*; D013997:Time Factors; D014421:Turkey / Q000453:epidemiology; D014777:Virus Diseases / Q000453:epidemiology* / Q000209:etiology
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D004317:Doxorubicin